Mirtazapina Krka (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and by antagonizing postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while reducing histamine‑mediated sedation.

The appropriate dose of Mirtazapina Krka is determined by the prescribing clinician based on the individual patient's clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional medical guidance.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing patients. The decision should be made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its receptor profile. It often produces strong sedative effects and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, whereas SSRIs are generally more activating and have a different side‑effect spectrum.

Mirtazapina Krka should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mirtazapina Krka is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe neutropenia, hepatic dysfunction, and rare cases of Stevens‑Johnson syndrome. Additionally, patients should be monitored for emergence or worsening of suicidal thoughts, especially during the initial treatment period.

Mirtazapina Krka is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) unless a washout period of at least 14 days has been observed. Caution is also advised for individuals with severe hepatic impairment.